biotech / news / / Business Standard
Mounjaro generated $8.7 billion for Lilly in the first quarter of 2026, outperforming Merck’s Keytruda, which posted sales of $7.9 billion.
Mounjaro became the world's best-selling drug in Q1 2026, surpassing Keytruda.
KEY POINTS
- Lilly's tirzepatide products, Mounjaro and Zepbound, generated $36.5 billion in 2025 combined.
- Keytruda's sales are threatened by a 2028 patent expiration, prompting Merck to shift focus.
- Lilly’s tirzepatide drugs outperformed despite entering the market after Novo Nordisk’s GLP-1 drugs.
COMPANIES
Summarized by Newsio from Business Standard. How we summarize →